medigraphic.com
Órgano oficial de la Facultad de Odontología, UNAM

2013, Number 1

Rev Odont Mex 2013; 17 (1)

Bisphosphonate-associated jaw osteonecrosis. Clinical case presentation

Fernández LRG, Arellano FÁM, Velázquez SSN

Language: Spanish
References: 13
Page: 47-50
PDF size: 395.68 Kb.


ABSTRACT

The aim of the present paper was to present the association between mandibular osteonecrosis and use of bisphosphonates for therapeutic purposes. Bisphosphonates are drugs used for the treatment of primary and secondary bone disorders. They are mainly used for local and general osteoporosis treatment, metabolic bone diseases, soft tissue calcification as well as hypercalcemia occurrence, among others. They can also act as antineoplastic agents through the inhibition of activation of cancer-linked proteins. In recent years, bisphosphonates have been used to prevent post-menopausae osteoporosis, since they enhance mineral density increase in bone and therefore contribute to a decrease in fractures. The clinical case here presented is that of a 61 year old female patient with previous history of breast cancer and ongoing 3 year bisphosphonate intake. The patient presented asymptomatic, spontaneous bone exposition. Surgical and medical handlings of the case are presented, as well as its evolution.


REFERENCES

  1. Goodman, Gilman. Las bases farmacológicas de la terapéutica. 10ª Edición. Vol I. México: Editorial McGraw Hill. 2003: 1604-05, 1666-1673.

  2. Mycek M. Farmacología. 2a. Edición. México: Editorial McGraw Hill, 2004: 559-560.

  3. Marx RE. Oral and intravenous bisphosphonate-induced osteonecrosis of de jaws, history, etiology, prevention, and treatment. Chicago: Editorial Quintessence Publishing Co. Inc, 2007: 1-96.

  4. Purriños L. Paget óseo. Guías Clínica 2005; 5(17): 1-2.

  5. Escobar L, López J, Marques MS, Chimenos K. Osteonecrosis de los maxilares asociada a bifosfonatos: revisión sistémica. Av Odontoestomatología 2007; 23(2): 91-101.

  6. Luchetti CG, Napal J, Barrales J, Yantorno S, Milone J, Kitrilakis AE. Osteonecrosis mandibular asociada a bifosfonatos. Ginecol y Obstet Mex 2007; 75 (11) 655-660.

  7. Fleish H. Bisphosphonates: mechanisms of action. Endocr Rev 1998; 19: 80-100.

  8. Rang cols. Farmacología. 5a. Edición. Madrid: Editorial Elsevier, 2004: 451-452.

  9. Barrios GE, García NV. Uso de bisfosfonatos en la infancia. Centro de Salud Playa San Juan BSCP Can Ped 2005; 29(2): 7-12.

  10. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004; 62: 527-534.

  11. Anguita T, Argurto J, Roa I, Laissle G. Osteonecrosis asociada al uso de bifosfonatos: A propósito de un caso clínico. Rev Med Chile 2006; 134: 1161-1165.

  12. Barrientos FJ, Peral B, de la Peña G, Sánchez LA, García JM, Serrat A et al Osteonecrosis de los maxilares inducida por bisfosfonatos: prevención y actitud terapéutica. Rev Esp Cir Oral y Maxillofac 2007; 29: 295-308.

  13. León A. A time for perspective on bisphosphonates. J Oral Maxillofacial Surgery 2004; 65: 527-534.




2020     |     www.medigraphic.com